IMMP - Immutep gets positive EMA feedback for development of eftilagimod alpha in breast cancer

Immutep (NASDAQ:IMMP) has received positive feedback from the EMA regarding its clinical development program for lead product candidate, eftilagimod alpha ((efti)), in breast cancer. In its scientific advice the EMA has supported the company’s view to continue the development of efti in metastatic breast cancer (MBC) in a Phase III clinical trial. As the planned Phase III trial is intended to take place across multiple countries, additional interactions with the EMA and other regulators, including with the US FDA to generate a final study design are ongoing, the company said. Shares up more than 3% premarket.

For further details see:

Immutep gets positive EMA feedback for development of eftilagimod alpha in breast cancer